Patient-associated risk factors for severe anemia in patients with advanced ovarian or breast cancer receiving olaparib monotherapy: A multicenter retrospective study

プレスリリースされた河添仁准教授ほかの論文は下記で読むことができます(YS) https://t.co/dIVgIfsqNm 治療開始前の赤血球パラメータおよび遺伝子BRCA1/2変異の測定で がんの標準治療オラパリブ療法による重篤な貧血を予測可能に：[慶應義塾] https://t.co/XZAytQhaGb

Tashiro R et al Patient-associated risk factors for severe #anemia in patients with advanced ovarian or #breastcancer receiving olaparib monotherapy: A multicenter retrospective study #OvarianCancer Read here https://t.co/n90BHGgRDo https://t.co/PN7hWHxGKc

📣 Patient-associated risk factors for severe #anemia in patients with advanced ovarian or #breastcancer receiving olaparib monotherapy: A multicenter retrospective study 👨‍⚕️👩‍⚕️ Tashiro R et al Read here 👉 https://t.co/dsOIpAPMLz #OvarianCancer

Patient-associated risk factors for severe anemia in patients with advanced ovarian or breast cancer receiving olaparib monotherapy: A multicenter retrospective study: Background, Olaparib-induced anemia is a frequently occurring… #oncology https://t.co/I